内科学-急性白血病(英文)_第1页
内科学-急性白血病(英文)_第2页
内科学-急性白血病(英文)_第3页
内科学-急性白血病(英文)_第4页
内科学-急性白血病(英文)_第5页
已阅读5页,还剩89页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

leukemia1LeukemiaDefinition:Agroupofmalignantclonalmalignantdiseaseofhematopoietictissue.Blockageofcelldifferentationindifferentstages.Accumulationofleukemiccellsinbonemarrow orotherorgans.Impairedproductionofnormalbloodcells.2ProgenitorcellStemcell3Normobalst原红Basophilicnormoblast早幼红Polychromaticnormoblast中幼红Ortho-chromaticnormoblast晚幼红4Myeloblast原粒Promyelocyte早幼粒Myelocyte中幼粒Metamyelocyte晚幼粒bandcell杆状核Segmentedcell分叶核5Monoblast原单Promonocyte幼单核Monocyte单核6Lymphoblast原淋Prolymphocyte幼淋Lymphocyte成熟淋Lymphocyte成熟淋7Megakaryoblast原巨核Promegakaryocyte幼巨核Granularmegakaryocyte颗粒巨核Platelate-formingmegakaryocyte产板巨核89CategoryofLeukemia

AcuteLymphoblasticLeukemia(ALL)AcuteLeukemia AcuteMyeloidLeukemia(AML) ChronicMyeloidLeukemia(CML)ChronicLeukemia ChronicLymphocyticLeukemia(CLL)10Acutemyelogenousleukemia(AML)Acutemyelogenousleukemia(AML)isaclonalmalignantdiseaseofhematopoietictissuesthatischaracterizedbyaccumulationofabnormalleukemicblastcells,principallyinthemarrowandimpairedproductionofnormalbloodcells.Thus,theleukemiccellinfiltrationinmarrowisaccompanied,nearlyinvariably,byanemiaandthrombocytopenia.Theabsoluteneutrophilcountmaybelowornormal,dependingonthetotalwhitecellcount.11IncidenceofAMLIncidenceRatesbyRaceRace/EthnicityMaleFemaleAllRaces4.3per100,000men3.0per100,000womenWhite4.5per100,000men3.1per100,000womenBlack3.5per100,000men2.8per100,000womenAsian/PacificIslander3.5per100,000men2.8per100,000womenAmericanIndian/AlaskaNativea2.5per100,000men3.1per100,000womenHispanicb3.5per100,000men2.7per100,000womenAgeadjustedincidence3.6per100,000.

Medianageatdiagnosis:66years.

LifetimeriskofadiagnosisofAML:0.39%ofpeoplebornnow.

NationalCancerInstitute.SEERStatSheets:AcuteMyeloidLeukemia.

/statfacts/html/amyl.html12AgedistributionofAML13AgedistributionofALL14IncidenceofLeukemiaInChina:AcuteLeukemia>ChronicLeukemiaAdult:AML>ALLChildren:ALL>AML15EtiologyofLeukemiaVirus:HTLV-I,HTLV-II,EBIonizingRadiation:AtomicbombexposureChemicalAgents:Benzene;cytotoxicdrugschloramphenicol(氯霉素);phenylbutazone(保泰松).HereditaryFactors:Downsyndrome,21trisomy(三体)16ACUTE LEUKEMIA17FABclassificationofALLL1:smalllymphoblastictypeL2:largelymphoblastictypeL3:largelymphoblastictypewithprominentcytoplasmicvacuolization18

AcuteLymphocyticleukemia(L1)

Theblastcellshaveahighnucleocytoplasmicratio,lackvisiblenucleoliandarerelativesmall.19AcuteLymphocyticLeukemia(L2)

Theblastcellsaremainlylargeandhaveoneortwoprominentnucleoli,whichrangeinsizefromsmalltolarge.20AcuteLymphocyticLeukemia

(L3)

Theblastcellshaveprominentcytoplasmicbasophiliaandareheavilyvacuolated

21FABclassificationofAMLM0:AcuteMyelocyticleukemiawithminimallydifferentiationM1:AcuteMyeloblasticLeukemia(withoutmaturation)M2:AcuteMyeloblasticLeukemia(withmaturation,M2a,M2b)M3:AcutePromyelocyticLeukemia(M3a,M3b)M4:AcuteMyelomonocyticLeukemia(M4a,M4b,M4c,M4EO)M5:AcuteMonocyticLeukemia(M5a,M5b)M6:AcuteErythroleukemiaM7:AcuteMegakaryoblasticLeukemia22FABM0type.BlastcellswithnoevidentfeaturesofdifferentiationandwithnegativereactionsforSudanblackBandmyeloperoxidase.Onimmunophenotypicanalysis,allBandTmarkerswerenegativebuttherewasexpressionofCD13,CD33.andCD34.FABM1type.BlastcellsaresmalltomediuminsizewithahighnucleocytoplasmicratioandoneofthemcontainsanAuerrod.SudanblackBandperoxidasereactionswerepositive.Peripheralbloodfilm.Auerrod23FABM2type.ThereisdifferentiationtopromyelocytesandthereisoneneutrophilandablastcellcontaininganAuerrod.Bonemarrowfilm.FABM3type.Blastcellsareinaminority,thedominantcellbeingahypergranularpromyelocytes,somewithbundlesofAuerrods.BonemarrowfilmAuerrods24FABM4category.Therearesomeblastsshowinggranulocyticdifferentiationandothersshowingmonocyticdifferentiation.Granulocyticdifferentiationismoreobviousinthebonemarrow(left)andmonocyticintheperipheralblood(right).Bonemarrowandperipheralfilm.FABM4category,witheosinophilicdifferentiation.ThiscategoryofAMLisoftenreferredtoasM4EOAML.Therearematureeosinophilsandeosinophilprecursors.Thelatterhavelargepro-eosinophilicgranules,whichhavebasophilicstainingcharacteristics.Bonemarrowfilm.leftright25FABM5acategory.Theblastsarelargewithabundantcytoplasm.Theyshowlittlesignsofdifferentiation,butonecellhasanindentednucleus.Nucleoliarelargeandprominent.Sometimestherearefineazurophilic(嗜苯胺蓝颗粒)granules.Bonemarrowfilm.FABM5bcategory.Monocyticdifferentiationisapparent.Bonemarrowfilm.26FABM6showingerythropoiesisthatisdysplasticandgrosslymegaloblastic(巨幼红细胞);thereisanexcessofproerythroblastsbutalsoofimmaturegranulocytes,includingblastcells.Bonemarrowfilm.FABM7category.Bonemarrowtrephinebiopsyshowsblastcells(left)andincreasedreticulindeposition(right).2728FlowchartshowinghowtheWHOhierarchicalclassificationisapplied.29AML的WHO分型

伴有再现性遗传学异常的AML伴有t(8;21)(q22;q22)(AML1/ETO)的AML伴有inv(16)(p13q22)或t(16;16)(p13;q22)(CBF/MYH11)和异常骨髓嗜酸细胞的AML伴有t(15;17)(q22;q12)(PML/RAR)的APL伴有11q23(MLL)异常的AML伴有多系病态造血的AML由MDS或MDS/MPD发展而来的AML无先前的MDS或MDS/MPD病史但二系或三系病态造血细胞50%治疗相关性AML和MDSt-AML和t-MDS烷化剂或放疗所致的AML/MDSDNA柘扑异构酶抑制剂所致的AML/MDS一些可能为ALL无法按上述分型的白血病NOC-AML急性微分化白血病急性未分化白血病急性部分分化的白血病急性粒单细胞白血病急性单核细胞白血病急性红血病急性红白血病和纯红血病急性巨核细胞白血病急性嗜碱细胞白血病急性全髓细胞增生伴骨髓纤维化髓系肉瘤305-year12%5-year40%5-year61%31ClinicalFeatures

Anemia----pallor,weaknessFever----mainlyduetoinfection(G-bacilli)

Bleeding----skin,nasal,gum,intracranial(颅内)Infiltration----organsandtissues32CausesofAnemiaDecreasedproductionoferythrocytesShortenedredbloodcellsurvivaltimeHemorrahagePost-chemotherapy33CausesofinfectionReducednormalgranulocytesinnumberImpairedfunctionofgranulocytesWeakenedcellularimmunityPost-chemotherapyeffects34CausesofBleedingQuantityandqualityofplateletPerivascularinfiltrationofleukemiccellsCoagulationabnormalities(凝血异常)DIC:releaseoftissuefactor-likeprocoagulants(促凝物质)fromgranuleswithintheleukemiccells35Leukemiainfiltration

Lymphadenopathy,Hepatomegaly,Splenomegaly:especiallyinALLBone(sternumtenderness,胸骨压痛)andJointChloroma(绿色瘤):AMLOralCavityandSkin:guminfiltrationfrequentlyseeninM4,M5CentralNerveSystemLeukemia(CNS-L):mainlyinALLTesticular(睾丸)Leukemia:mainlyinALL36guminfiltrationskinbleedingandinfiltration37LabFindings:PeripheralBlood

WBC-----5.0to50.0x109/L<1.0x109/Lor>100x109/LLeukemiccellsoftencanbeseenAleukemictype:WBCdecreasedwithoutleukemiccellsAnemia-----RBCcountandHbdecreasePlateletCount-----decreased38

AcuteLeukemia----PeripheralBlood

39LabFindings:PeripheralBlood

SubtypeaccordingtoperipheralbloodLeukemictype:

WBCincreasedwithleukemiccellsSubleukemictype:

WBCnormalrangewithleukemiccellsAleukemictype:

WBCdecreasedwithoutleukemiccells40LabFindings:BoneMarrow

GeneralAspects:HyperplasiaLeukemiccellsexcessivelyproliferationInhibitingothercelllinesLeukemiccells>20%41BoneMarrow

Acuteleukemia Normal42BonemarrowAML43BonemarrowofAPL44Renjihospital

ClinicalandmolecularcharacteristicsofAPL

45Bonemarrowofacutemonocyticleukemia46BonemarrowofALL47CytochemistryofleukemiccellsALLAMLAMoLPOX-+++-~+PAS+clumporgranular-/+diffused-/+diffusedNSENAP-↑-/+NotinhibitbyNaF↓/-++InhibitedbyNaFN/↑48

CytochemicalstainPOX

NSEPAS49POXofAPLSEofAPL50ImmunologicMarkers

LineageAntigen

B-cellCD19,CD20,CD21,CD22,HLA-DRT-cellCD1,CD2,CD3,CD4,CD5,CD7,CD8MyeloidCD13,CD14,CD15,CD33,CD4151ImmunologicMarkers

M1M2M3M4M5M6M7CD13+++++--CD33+++++--CD14-±-++--CD41------+52ImmunologicMarkers

LineageAntigenErythroidGlycophorinAMegakaryocyticCD41,CD42b,CD6153CytogeneticsandMolecularBiologyAMLM3t(15;17)(q22;q21)PML/RARRAR/PMLM4EOivn(16)(q22)CBFB/MYH11M2t(8;21)(q22;q22)AML1/ETOM5t/del(11)(q23)MLL/ENL

54PMLRARaPML-RARaRARa-PML15171517

CytogeneticsandMolecularBiologyofAPL55RISKSTATUSBASEDONCYTOGENETICSANDMOLECULARMUTATIONS56Distributionofcommoncytogeneticabnormalitiesinpatientsagedlessthanormorethan60.

57TheDFSandOSofcytogeneticchangesinAMLBetter-riskIntermediate-riskPoor-riskBetter-risk1Intermediate-riskPoor-risk58CytogeneticsandMolecularBiologyALLt(9;22)(q34;q11)BCR/ABLALL-L2t(1;19);t(4;11)ALL-L3t(8;14)(q24;q32)MYC/IgH

59RenatoBassanetal,2004,OncologyHematology60MICMCategoryM----morphologyI----immunologyC----cytogeneticsM----molecularbiology61LabFindings:Others

Hyperuricemia(高尿酸血症)----tumorcelllysisLactateDehydrogenase(LDH)increaseActivityoflysozyme(溶菌酶)increase, commoninM4orM5DIC:morecommoninAMLthanALL,especiallyinM3(APL)62LabfindingsCellularmorphologyBloodroutinebiochemistryimmunologyGenemutations:C-KIT、FLT3-ITD、NPM1、CEBPACytogeneticMolecularfeatures(PML/RARα、AML1/ETO、CBFb/MYH11、MLL)2.Labfindings63DiagnosiccriteriaClinicalmanifestationPeripheralbloodchangesAnemiaThrombocytopeniaLeukemiccellsBonemarrowexaminationleukemiccells>20%64DifferentialdiagnosisMyelodysplasticsyndromes(MDS)LeukemoidreactionAplasticanemia65Jamesw,etal.Blood,2002,100(7):229266ManagementGeneralmanagement:SupportivecarestreatingofongoinginfectionsandpreventingChemotherapy,usuallycombinedremedyProphylacticandtreatmentofextramedullaryleukemiaImmunotherapyBMT67ChemotherapyGOALS:AchieveCompleteRemmission(CR);ProlongDiseaseFreeSurvival(DFS);Curethedisease68PrinciplesofChemotherapySelectionofdrugsandprotocolsDrugsfocusingondifferentcellcyclesDrugsworkingcorporatelyNoseveroverlapoftoxicity69Anti-LeukemiaDrugs:

Killers:makingtheleukemiccellsdead---mostofthedrugsweuseInducerofdifferentiation:leadingtheblaststomatureones---ATRAPromotorofApotosis:leadingleukemiccellsto“naturaldeath”---As2O370StrategyofChemotherapyTherapeuticperiodandintermittentperiodRemissionInductionTherapyPost-RemissionTherapy71TreatmentInductionConsolidationmaintenance72Treatmentstrategy73ALL:RemissionInduction

DVPRegimen:Daunomycin(D)45mg/m2/d,D1-3(15-17)orIdarubicin(ID)8-12mg/m2/d,D1-3(15-17)Vincristine(V)1.4mg/m2/d,D1,8,15,22Prednisone(P)40mg/m2/d,D1-28CRrate: adult----80~90%74NCCNGuidelineforAML75AML:Remissioninduction

DARegimen:

Daunomycin(D)60-90mg/m2/d,D1-3

orIdarubicin(ID)8-12mg/m2/d,D1-3Ara-C(A)150mg/m2

/d,D1-7HARegimen:Harringtonin(H)3-4mg/d,D1-3Ara-C(A)150mg/m2/d,D1-7CRrate:65-85%76PostremissiontherapyAccordingtocytogeneticsandmolecularabnormalitiesBetter–riskorintermediate-risk(nodonor)HD-AraC2.0g/m2,q12h,d1,d2,d3Intermediate-risk:Allo-PBSCTPoor-risk:Allo-PBCST7778Acutepromyelocyticleukemia(APL))DiagnosisBM:cellularmorphologyCytogenetics:t(15;17)Molecularfeature:PML-RAROthers:t(11;17)→PLZF—RARα,NuMA–RARαt(5;17)→NPM—RARαAML-M3a79CytogeneticsandmolecularfeaturesofAPLcytogeneticsIncidenceinAPLFusiongeneClinicalfeaturest(15;17)(q22;q21)>95%PML-RARaATRA

sensitiveRARa-PMLArsenic

sensitivet(11;17)(q23;q21)0.8%PLZF-RARaATRAnosensitiveRARa-PLZFArsenic

resistancet(11;17)(q13;q21)rareNuMA-RARaATRAsensitivet(5;17)(q35;q21)<0.5%NPM-RARaATRAsensitiveRARa-NPMder(17)rareSTAT5b-RARa?ATRA

sensitive80InductiontherapyWBC>10X109/L(highrisk)ATRA:25mg/m2/d,d1-CRIDA:8mg/m2/d,d2,4,6,8;orDNR:45-60mg/m2/d,d1-3±Ara-CATO0.16mg/kg/d,d1-CRWBC<10X109/L(lowrisk)ATRA+IDA

orDNR+ATO81ConsolidationtherapyLowriskATRA:25mg/m2/d,d1-d14IDA:8mg/m2/d,orDNR60mg/m2/dx3dHighriskATRA+IDA8mg/m2/d,orDNR60mg/m2/dx3d+Ara-C150mg/m2/dx7d.ATRA+HHT2mg/m2/dx3d+Ara-C1.0g/m2q12hx3d.(1course)2courses2courses82MaintenancetherapyLowriskATRA:20mg/m2/dx14d.(onemonths)ATO:0.16mg/kg/dx14d,interval14d,0.16mg/kg/dx14d(thesecondandthirdmonths)

5cycles83MaintenancetherapyHighriskATRA:20mg/m2/dx14d.(onemonths)ATO:0.16mg/kg/dx14d,interval14d,0.16mg/kg/dx14d(thesecondandthirdmonths)MTX15mg/m2/wx4w6-MP50mg/m2/dx28d(thefourthmonths)

5cycles84DualMechanismofAs2O385ATRAandATOcombinationProcNatlAcadSciUSA.2004;101:5328-5335.

8687APLtherapy

PrimaryAPLATRA+As2O3+ChemotherapyHCR

CTX2~3courses

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论